Eliot Charles, MiroBio executive chairman
August 4, 2022 11:31 AM EDT
Deals

Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

Lei Lei Wu

News Reporter

While Gilead dropped dis­ap­point­ing da­ta on its Ar­cus-part­nered CD37 in­hibitor Wednes­day af­ter­noon, the bio­phar­ma is mak­ing moves to cush­ion its im­mune check­point pipeline. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times